Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Status:
Completed
Trial end date:
2019-04-29
Target enrollment:
Participant gender:
Summary
Background:
- Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets
CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab
pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a
phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile
supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase
III multicenter trial designed to confirm these results.